Sanofi has announced that it will lower the list price of its insulin drug, Lantus, by 78 percent and will set a $35 cap on out-of-pocket costs for all patients.
The price change and cap will go into effect starting January 1, 2024. They follow a series of moves made last year to lower the price of diabetes medicine, including the launch of an unbranded version of Lantus and a $35 cap for uninsured patients.
Yet, Olivier Bogillot, head of U.S. general medicines at Sanofi, said "the health system was unable to take advantage of it due to its inherent structural challenges."
“Sanofi believes that no one should struggle to pay for their insulin and we are proud of our continued actions to improve access and affordability for millions of patients for many years," he said. "Our decision to cut the list price of our lead insulin needs to be coupled with broader change to the overall system to actually drive savings for patients at the pharmacy counter.”
Sanofi will also cut the price of short-acting Apidra by 70 percent.
Exclusive: Behr’s Andy Lopez reveals how ChatHUE, a bold collaboration with Google, is using AI to transform how we explore, choose, and connect with color.
Brian Vendig, President & CIO of MJP Wealth Advisors, joins to break down Q2 bank earnings and what they signal for markets, investors, and the economy ahead.
Are Gen Z and Millennials done with alcohol? Bacardi's Tony Latham breaks down trends, new preferences, and insights from the 2025 Cocktail Trends Report.
Comscore’s Paul Dergarabedian breaks down the battle of summer blockbusters, from Superman to Jurassic World and Fantastic Four and what it means for studios.
VENU CEO JW Roth breaks ground on a 20,000-seat, state-of-the-art amphitheater in Texas—part of a $300M public-private expansion to redefine live music.
Despite healthcare spending cuts, medtech stocks like Edwards Life Sciences, Stryker, and Boston Scientific are rising, especially those serving older pati
The original Birkin bag created by Hermès for Jane Birkin in 1984 is up for auction in Paris. Sotheby’s expects the iconic bag to sell for hundreds of thousands of euros on Thursday.
Elon Musk’s artificial intelligence company is taking down antisemitic comments and other “inappropriate posts” made by its Grok chatbot, including some praising Adolf Hitler.
